- Spending on glucagon-like peptide-1 receptor agonists surged by over 500% from 2018 to 2023.
- Semaglutide and tirzepatide products contributed significantly to the rise in spending, accounting for 70% of all GLP-1 RA spending in 2023.
- The market share of GLP-1 RA products underwent substantial shifts over the study period.
- The study analyzed Symphony Health data capturing 85% of retail and 74% of mail order prescription fills.
- Limitations in the analysis included an inability to capture sales at compounding pharmacies, prescription indications, and adjustments for rebates and discounts.
Source: JAMA Network Open
